Cargando…
Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib
Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synerg...
Autores principales: | Xia, Hongping, Lee, Kee Wah, Chen, Jianxiang, Kong, Shik Nie, Sekar, Karthik, Deivasigamani, Amudha, Seshachalam, Veerabrahma Pratap, Goh, Brian Kim Poh, Ooi, London Lucien, Hui, Kam M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592242/ https://www.ncbi.nlm.nih.gov/pubmed/28900541 http://dx.doi.org/10.1038/cddiscovery.2017.58 |
Ejemplares similares
-
The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway
por: Chen, Jianxiang, et al.
Publicado: (2016) -
Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth
por: Wang, Yu, et al.
Publicado: (2019) -
The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015) -
Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers
por: Jiang, Xiaodan, et al.
Publicado: (2021) -
MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma
por: Xia, Hongping, et al.
Publicado: (2012)